Key facts
- This page summarizes Laurie Keating's Form 4 filing for Kalaris Therapeutics, Inc. (KLRS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Aug 2026, 16:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.